ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 5.5 | 5.1 | 6.7 |
| Total income | 5.5 | 5.1 | 6.7 |
| Profit before exceptional items & tax | 0.5 | -0.7 | 0.3 |
| Profit before tax | 0.5 | -0.7 | 0.3 |
| Net profit | 0.6 | -0.7 | 0.2 |
| Operating margin | 9.1% | -13.7% | 4.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +200.00% |
|---|---|
| Revenue, year on year | -17.90% |
BSE results filing, NSE: CHEMIESYNT. Figures extracted from the filing.
Chemiesynth (Vapi) Ltd: key numbers
- Share price
- ₹160.70
- Market cap
- ₹49.33 Cr
- Revenue (annual)
- ₹21.44 Cr
- Net profit (annual)
- ₹-0.99 Cr
- P/E (TTM)
- -59.0×Sector 35.5×
- Promoter holding
- 62.35%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Chemiesynth (Vapi) Ltd
All →Chemiesynth (Vapi) Q2 FY27 Results: Net Loss of ₹0.2 Cr, Loss Narrows
Chemiesynth (Vapi) Ltd reported un-audited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors approved these results alongside the statutory auditor's limited review report.
- Key figure
- Net loss ₹0.2 Cr
Chemiesynth (Vapi) Debt & Borrowing: ₹10 Cr
Chemiesynth's board approved allotment of 1 crore unlisted NCRPS at ₹10 par, raising ₹10 Crore. The 7-year, 5% unsecured shares are issued via private placement.
- Value
- ₹10.00 Cr
- Execution
- 7 years (28-10-2026 to 28-10-2033)
Chemiesynth (Vapi) Board Meeting Date
Chemiesynth (Vapi) Ltd notified a board meeting scheduled for 28 October 2026. The agenda includes approval of unlisted NCRPS allotment on private placement basis.
Chemiesynth (Vapi) Other Announcement
Chemiesynth (Vapi) Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the period ended September 30, 2026.
Chemiesynth (Vapi) Annual General Meeting
Chemiesynth (Vapi) Ltd held its 40th AGM, approving the adoption of financial statements and the reappointment of Mr. Rushabh Mehta as Director. Shareholders also approved an increase in authorised share capital to ₹18.25 Crore.
Chemiesynth (Vapi) Annual General Meeting
Chemiesynth (Vapi) Limited has issued a notice for its 40th Annual General Meeting scheduled for September 30, 2026. The filing includes the Annual Report web-link.